Finance

Lists
Why is URGN up 3,94%?
Dive Deeper
URGN:NASDAQ
Urogen Pharma Ltd
USD 38,28
+3,94%
(+1,45) 1D
USD 38,28
0,00% (0,00)
After hours
Closed: 12 Okt., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for URGN...
Open
USD 36,97
High
USD 38,32
Low
USD 36,20
Mkt. cap
1,87 mjd
Avg. vol.
888,61 k
Volume
531,00 k
52-wk high
USD 50,81
52-wk low
USD 16,18
EPS
-USD 1,98
Beta
1,57
Shares outstanding
48,88 m
No. of employees
300
Open
USD 36,97
High
USD 38,32
Low
USD 36,20
Mkt. cap
1,87 mjd
Avg. vol.
888,61 k
Volume
531,00 k
52-wk high
USD 50,81
52-wk low
USD 16,18
EPS
-USD 1,98
Beta
1,57
Shares outstanding
48,88 m
No. of employees
300
News stories
From web sources and news partners
About Urogen Pharma Ltd
CEO-
Employees300
Founded2004
HeadquartersNew York Stad, New York, Verenigde State van Amerika
Sector-
Websiteurogen.com
Analyst ratings
Based on 5 analysts giving stock ratings to URGN in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for URGN in the last 3 months.
Highest
Current USD 38,28
USD 75,00 (+95,92%)
Average
USD 60,20 (+57,26%)
Lowest
USD 48,00 (+25,39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
USD 75,00
+95,9%
08/21/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
USD 60,00
+56,7%
08/06/2026
Paul Choi
Goldman Sachs
Hold
Maintained
USD 48,00
+25,4%
08/05/2026
Michael Schmidt
Guggenheim
Buy
Maintained
USD 58,00
+51,5%
08/05/2026
Tara Bancroft
TD Cowen
Buy
Reiterated
USD 60,00
+56,7%
08/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
USD 32,00
-16,4%
06/03/2026
Kevin DeGeeter
Ladenburg Thalmann & Co.
Buy
Initiated
USD 43,00
+12,3%
05/11/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
USD 40,00
+4,5%
04/20/2026
Amin Makarem
Jefferies
Buy
Initiated
USD 40,00
+4,5%
04/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
27,48 m
37,84 m
50,96 m
72,46 m
Cost of goods sold
3,28 m
3,29 m
4,14 m
6,57 m
Cost of revenue
3,28 m
3,29 m
4,14 m
6,57 m
Research and development expenses
14,01 m
14,31 m
15,60 m
17,34 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37,58 m
39,35 m
51,49 m
48,44 m
Operating expense
51,59 m
53,66 m
67,08 m
65,77 m
Total operating expenses
54,87 m
56,95 m
71,22 m
72,34 m
Operating income
-27,39 m
-19,12 m
-20,26 m
111,00 k
Other non operating income
-4,82 m
-4,66 m
-4,83 m
-4,89 m
EBT including unusual items
-34,40 m
-26,64 m
-28,35 m
-8,72 m
EBT excluding unusual items
-34,40 m
-26,64 m
-28,35 m
-8,72 m
Income tax expense
-1,05 m
-275,00 k
-4,77 m
5,63 m
Effective tax rate
3,06%
1,03%
16,83%
-64,54%
Other operating expenses
-
-
-
-
Net income
-33,35 m
-26,36 m
-23,57 m
-14,35 m
Net profit margin
-121,34%
-69,68%
-46,26%
-19,81%
Earnings per share
-0,69
-0,53
-0,47
-0,28
Interest and investment income
1,18 m
908,00 k
931,00 k
946,00 k
Interest expense
-3,37 m
-3,77 m
-4,18 m
-4,89 m
Net interest expenses
-2,20 m
-2,86 m
-3,25 m
-3,94 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-27,31 m
-19,04 m
-20,19 m
189,00 k
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme